rimonabant rimonabant rimonabant (also known as sr141716; trade names acomplia, zimulti) is an anorectic antiobesity drug that was first approved in europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the united states. rimonabant is an inverse agonist for the cannabinoid receptor cb1 and was the first drug approved in that class. rimonabantclinical dataahfs/drugs.comconsumer drug informationlicense data eu ema: by inn pregnancycategory not assigned, use not recommended routes ofadministrationoralatc codea08ax01 (who) legal statuslegal status withdrawn from european and brazilian markets; not approved elsewhere pharmacokinetic databioavailabilityundeterminedprotein bindingnearly 100%metabolismhepatic, cyp3a4 involvedelimination half-lifevariable:6 to 9 days with normal bmi16 days if bmi >30excretionfecal (86%) and renal (3%)identifiers iupac name 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-(piperidin-1-yl)-1h-pyrazole-3-carboxamide cas number168273-06-1 yhcl: 158681-13-1 ypubchem cid104850iuphar/bps743drugbankdb06155 ychemspider94641 yuniirml78en3xehcl: hl0v2lqz09 ykeggd05731 ychemblchembl111 ycomptox dashboard (epa)dtxsid3046453 echa infocard100.210.978 chemical and physical dataformulac22h21cl3n4omolar mass463.79 g·mol−13d model (jsmol)interactive image smiles o=c(nn1ccccc1)c4nn(c2ccc(cl)cc2cl)c(c3ccc(cl)cc3)c4c inchi inchi=1s/c22h21cl3n4o/c1-14-20(22(30)27-28-11-3-2-4-12-28)26-29(19-10-9-17(24)13-18(19)25)21(14)15-5-7-16(23)8-6-15/h5-10,13h,2-4,11-12h2,1h3,(h,27,30) ykey:jzcpyujpearbjl-uhfffaoysa-n y (verify) history